stockrow
Friday 6 November 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- +35.3%
- Free cash flow
- +12.8%
- Total debt
- +0.05%
Quarter to September 2026, against a year earlier
11.23
8.61
−43.40%
Follow BDSX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.02 | 2.26 | 1.46 | 0.58 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(44.15) | (148.64) | (13.77) | 66.00 | |
P/B ratio |
36.66 | 25.39 | 15.33 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.20 | 2.42 | 1.67 | 0.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.55) | (12.56) | (6.48) | (3.43) | |
EV/FCF |
(17.49) | (12.21) | (6.37) | (3.37) | |
Quick Ratio |
2.63 | 2.56 | 2.42 | 1.61 | |
Current Ratio |
2.96 | 2.85 | 2.82 | 1.87 | |
Net Debt/EBITDA |
0.00 | (4.63) | (4.70) | (125.39) | |
Debt/Assets |
50.19% | 49.11% | 49.12% | 54.24% | |
Debt/Equity |
5.43 | 5.12 | 5.09 | (19.25) | |
Asset Turnover |
1.15 | 1.12 | 1.06 | 0.96 | |
Operating CF/Net income |
0.90 | 0.21 | 1.30 | (0.20) | |
Capex/Depreciation |
0.00 | (0.14) | (0.08) | (0.06) | |
Interest Coverage |
— | (2.72) | (3.14) | (0.96) | |
Research and Development Expense of Revenue |
12.45% | 11.67% | 12.85% | 9.98% | |
Selling, General and Administrative Expense of Revenue |
93.59% | 90.40% | 94.94% | 79.89% | |
Intangible Assets out of Total Assets |
0.19 | 0.19 | 0.20 | 0.22 | |
Share Based Compensation of Revenue |
3.54% | 3.05% | 4.36% | 3.74% | |
Graham Net Nets |
(0.14) | (0.18) | (0.32) | (1.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 5.97 | |
Earnings Yield |
(9.25%) | (14.06%) | (28.00%) | (71.32%) | |
Free Cash Flow Yield |
(6.06%) | (8.79%) | (18.03%) | (46.11%) | |
Revenue per Share |
2.26 | 2.61 | 2.65 | 3.81 | |
Operating CF per Share |
(0.68) | (0.15) | (1.05) | 0.10 | |
Capex per Share |
(0.06) | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.73) | (0.18) | (1.07) | 0.09 | |
Cash per Share |
2.67 | 2.91 | 2.65 | 2.51 | |
Shareholders Equity per Share |
0.81 | 0.89 | 0.95 | (0.33) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.81 | 0.89 | 0.95 | (0.33) | |
Free Cash Flow |
(7.80) | (1.82) | (10.31) | 0.67 | |
Working Capital |
27.89 | 28.27 | 26.42 | 15.08 | |
Capital Expenditures |
(0.60) | (0.25) | (0.14) | (0.10) | |
Net Current Asset Value |
(43.13) | (42.62) | (44.59) | (57.42) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.90 | 8.28 | 8.57 | 8.82 | |
Average Payables |
3.12 | 2.57 | 3.29 | 2.64 | |
Average Assets |
91.33 | 91.53 | 90.44 | 92.36 | |
Average Common Equity |
3.48 | 5.14 | 10.10 | 9.21 |
Columns are period end dates · fundamentals updated 5 Nov 2026